Cellular immunotherapy for refractory hematological malignancies

BACKGROUND: Acute myeloid leukemia (AML) and other aggressive refractory hematological malignancies unresponsive to upfront therapy remain difficult conditions to treat. Often, the focus of therapy is centered on achieving complete remission of disease in order to proceed with a consolidative stem c...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Reagan, John L, Fast, Loren D, Safran, Howard, Nevola, Martha, Winer, Eric S, Castillo, Jorge J, Butera, James N, Quesenberry, Matthew I, Young, Carolyn T, Quesenberry, Peter J
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Protocol
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3689050/
https://ncbi.nlm.nih.gov/pubmed/23782682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-150
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky